Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Synthetic Biology topic
No spam. Unsubscribe anytime.
Synthetic‑biology speakers showcase antigen‑density sensors, modular receptors and secretion circuits to improve CAR‑T precision
Summary
Presenters described synthetic Notch antigen‑density circuits, new engineered binding domains, and RNA‑level and membrane‑release systems to make immune cells sense tumor microenvironment signals and regulate payload expression (examples: tumor‑restricted CAR expression, KRAS‑sensing circuits driving IL‑12 in model cells).
Several talks focused on tools from synthetic biology that aim to increase the precision and safety of cell therapies and to provide modular ways to probe microenvironmental signals.
One presenter described synNotch‑based antigen‑density sensing: a low‑affinity synNotch receptor detects high antigen density and then activates transcription of a high‑affinity CAR, producing an ultrasensitive response that spares normal tissues with low antigen expression. He also discussed developing compact binder domains ('sherpa bodies') to enable combinatorial antigen recognition and logic gating in engineered T cells.
A complementary set of talks described RNA‑level receptors and regulated secretion platforms. One group presented an mRNA‑deliverable system in which a single RNA encodes (1) a translatable payload, (2) a truncated editing enzyme fused to a deaminase domain, and (3) a tether that recruits the editing enzyme only when two ligand‑responsive proteins (for example, a GPCR and arrestin) are brought together; in double‑helix edited regions, A→I editing can remove an in‑frame stop codon and enable payload translation only when the extracellular ligand is present. The same group presented a modular 'release' system that tethers a therapeutic protein to the membrane by a retention sequence; a sequence‑specific protease input frees the protein for secretion, enabling two‑step control (sense → release).
Another presenter described engineering hypoxia‑responsive gene circuits to restrict CAR expression to low‑oxygen microenvironments and the use of quantitative models to optimize circuit dynamics, and a modular cytokine‑sensor architecture (MACEA) to make soluble factors feed synthetic circuits with predictable output.
Speakers emphasized that these engineered parts can serve two complementary purposes: (1) therapeutic precision by limiting off‑tumor activity, and (2) experimental probes to measure or perturb local microenvironmental signals in vivo when combined with appropriate delivery methods.
